Nuvectis Pharma (NVCT)
(Real Time Quote from BATS)
$6.20 USD
-0.47 (-7.05%)
Updated Sep 16, 2024 01:52 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Cash flow Statements
Fiscal Year End for Nuvectis Pharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -22.26 | -19.09 | -12.89 | -0.01 | NA |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change from Assets/Liabilities | 1.60 | 3.82 | 1.49 | 0.01 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 4.71 | 1.71 | 1.89 | 0.00 | NA |
Net Cash From Operating Activities | -15.95 | -13.56 | -9.50 | 0.00 | NA |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 16.48 | 31.88 | 15.25 | 0.00 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -1.39 | -4.07 | 0.00 | 0.00 | NA |
Net Cash from Financing Activities | 15.09 | 27.81 | 15.25 | 0.00 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -0.87 | 14.25 | 5.74 | 0.00 | NA |
Cash at Beginning of Period | 19.99 | 5.74 | 0.00 | 0.00 | NA |
Cash at End of Period | 19.13 | 19.99 | 5.74 | 0.00 | NA |
Diluted Net EPS | -1.43 | -1.51 | -3.02 | NA | NA |
Fiscal Year End for Nuvectis Pharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -8.60 | -4.17 | -22.26 | -15.64 | -9.76 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | -1.34 | -1.48 | 1.60 | 0.05 | -1.46 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.56 | 1.30 | 4.71 | 3.49 | 2.35 |
Net Cash From Operating Activities | -7.38 | -4.36 | -15.95 | -12.10 | -8.86 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.58 | 4.85 | 16.48 | 15.58 | 14.44 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.21 | -0.15 | -1.39 | -1.41 | -0.97 |
Net Cash from Financing Activities | 6.37 | 4.70 | 15.09 | 14.17 | 13.47 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -1.01 | 0.34 | -0.87 | 2.07 | 4.61 |
Cash at Beginning of Period | 19.13 | 19.13 | 19.99 | 19.99 | 19.99 |
Cash at End of Period | 18.12 | 19.46 | 19.13 | 22.06 | 24.60 |
Diluted Net EPS | -0.26 | -0.25 | -0.41 | -0.37 | -0.38 |